Cancer Chemotherapy and Biotherapy-5판

Table of Contents
1 Clinical strategies for cancer treatment : the role of drugs 1
2 Preclinical aspects of cancer drug discovery and development 15
3 Pharmacokinetics 31
4 Infertility after cancer chemotherapy 45
5 Carcinogenesis of anticancer drugs 70
6 Antifolates 91
7 5-fluoropyrimidines 125
8 Cytidine analogues 183
9 Purine antimetabolites 212
10 Hydroxyurea 229
11 Antimicrotubule agents 237
12 Clinical and high-dose alkylating agents 283
13 Nonclassic agents 310
14 Cisplatin, carboplatin, and oxaliplatin 332
15 Bleomycin 344
16 Antitumor antibiotics 359
17 Topoisomerase I-targeting drugs 371
18 Anthracyclines and anthracenediones 414
19 Topoisomerase II inhibitors : the epipodophyllotoxins, acridines, and ellipticines 451
20 Asparaginase 476
21 Delivering anticancer drugs to brain tumors 484
22 Food and drug administration role in oncology product development 502
23 Central venous catheters : care and complications 516
24 Pharmacogenetics 529
25 New targets for anticancer therapeutics 549
26 Bisphosphonates 579
27 Thalidomide and its analogs for the treatment of hematologic malignancies, including multiple myeloma, and solid
tumors 587
28 Inhibitors of tumor angiogenesis 605
29 Proteasome inhibitors 621
30 Molecular targeted drugs and growth factor receptor inhibitors 641
31 Antibody therapies of cancer 666
32 Interferons 699
33 Adoptive cellular therapies 718
34 Cancer vaccines 739
35 Hematopoietic growth factors 747
36 Interleukins 767
37 Hormonal therapy for breast cancer 809

Read an Excerpt
The skilled physicians treating patients with cancer have a daunting task in that they need to understand pharmacology,
pharmacokinetics, pharmacogenetics, pharmacodynamics, drug metabolism, drug resistance, cancer cell biology, normal
cell biology, and myriad drug interactions, in addition to considerations of alterations in physiology caused by the
cancer or associated with concurrent disease or advanced age that influence these distinct facets that in turn
influence drug action. In this book, we have attempted to incorporate relevant information that will assist the
caregiver in planning the optimal treatment approach for each individual patient. It is our intention to keep the
information in this text up to date through the addition of relevant information on newly approved drugs to the new
online version of this book that appears at http://www.lwwoncology.com. We look forward to your feedback about how to
make this book more useful to you.
뾄ruce A. Chabner, M.D.,Dan L. Longo, M.D.